Assessment of causes of death in a prostate cancer screening trial.
about
Non-Steroidal Anti-Inflammatory Drugs and Cancer Death in the Finnish Prostate Cancer Screening TrialScreening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up.Standardisation of information submitted to an endpoint committee for cause of death assignment in a cancer screening trial – lessons learnt from CAP (Cluster randomised triAl of PSA testing for Prostate cancer).Contemporary accuracy of death certificates for coding prostate cancer as a cause of death: Is reliance on death certification good enough? A comparison with blinded review by an independent cause of death evaluation committeeAbsolute Effect of Prostate Cancer Screening: Balance of Benefits and Harms by Center within the European Randomized Study of Prostate Cancer Screening.Differences in endpoints between the Swedish W-E (two county) trial of mammographic screening and the Swedish overview: methodological consequences.Does the source of death information affect cancer screening efficacy results? A study of the use of mortality review versus death certificates in four randomized trials.Impact of cause of death adjudication on the results of the European prostate cancer screening trial.Prostate Cancer and Socioeconomic Status in the Finnish Randomized Study of Screening for Prostate Cancer.Use of non-steroidal anti-inflammatory drugs and prostate cancer survival in the Finnish prostate cancer screening trial.Digoxin and prostate cancer survival in the Finnish Randomized Study of Screening for Prostate Cancer.High accuracy of Swedish death certificates in men participating in screening for prostate cancer: a comparative study of official death certificates with a cause of death committee using a standardized algorithm.Prostate cancer mortality in the Finnish randomized screening trial.Population-based comparative effectiveness of nephron-sparing surgery vs ablation for small renal masses.A randomized trial of early detection of clinically significant prostate cancer (ProScreen): study design and rationale.High Norwegian prostate cancer mortality: evidence of over-reporting.Design issues in cancer screening trials.Cancer mortality does not differ by antiarrhythmic drug use: A population-based cohort of Finnish men.
P2860
Q28551492-9A51A2ED-36AA-40A1-BBB8-7481AC5C35F6Q34041688-1DD34F34-BBB7-4728-BB1B-0CEEC7DE15BEQ35547542-F99ECEBC-5922-4DA5-8FC8-4C7C8BD4F23EQ37061367-4A6D9064-21FC-4601-8931-B87D3F56059BQ37109441-E8ABA1B0-42ED-4108-816E-C179E3AE8094Q37535367-906D297F-9CFF-4201-BED9-E83A8593B39AQ37692736-B0C2E805-DBAE-4231-8E22-B5FF9A941FB4Q39180719-BE5BD2CD-E9E9-488A-BAB8-0D6C0A4D9145Q39253189-2A92FB37-F780-4290-B69A-8ADC3EC8CFC6Q41670120-F0148A31-2BAC-4FBB-B8AE-8D31394ECF10Q44228168-3166178D-CFC7-42AB-AD90-0F7A29702AE9Q44629190-EB62D70E-05C6-49C9-BE26-E2DD131F5C7FQ45226686-55D8FEA6-6FEA-47FC-B66B-CFB06088FFF6Q46006407-5D434CF4-97D0-4184-AEF3-16EF37BC60B8Q47759609-77C56775-751D-4759-BF39-27B5B56A5AC1Q48258581-F0A73EC1-A956-43CE-9334-11C2E205E9FDQ48821757-1C01ABB8-149F-470A-9BC6-18B6CE2D8A4BQ55608083-3684F781-BD6F-4633-B3B9-EAB6F53DCA19
P2860
Assessment of causes of death in a prostate cancer screening trial.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Assessment of causes of death in a prostate cancer screening trial.
@en
type
label
Assessment of causes of death in a prostate cancer screening trial.
@en
prefLabel
Assessment of causes of death in a prostate cancer screening trial.
@en
P2093
P2860
P356
P1476
Assessment of causes of death in a prostate cancer screening trial.
@en
P2093
Jorma Lahtela
Liisa Määttänen
Pekka Karhunen
Tuukka Mäkinen
P2860
P304
P356
10.1002/IJC.23126
P577
2008-01-01T00:00:00Z